The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

To cope with the insecurities and loneliness, as a single child from a single-parent family, Chan’s drug addiction escalated ...

Ebglyss® (lebrikizumab) to treat moderate-to-severe atopic dermatitis1 (eczema) has officially been listed on Québec's public ...

Nektar Therapeutics was founded in 1990, but it doesn't have any commercial-stage drugs that generate revenue righ ...

The White House has been pursuing efforts to lower U.S. drug costs by linking them to the cheaper prices paid abroad.

Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock ...

Researchers found antibiotic-resistant bacteria driving nearly 80 per cent of sepsis cases in newborns in a number of Asian ...

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...

True or False: Early data from a randomized trial showed that acetaminophen (Tylenol) led to a greater risk of eczema in ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock gained 1.5% in Monday’s premarket trading after the U.S. Food and Drug Administration approved its ZORYVE cream for treating mild to ...

AbCellera Biologics eyes long-term growth with a new facility, clinical trial progress, and a pivot to proprietary drug ...